Early trial of GEN3017 for Hard-to-Treat lymphomas ends early
NCT ID NCT06018129
First seen Nov 01, 2025 · Last updated May 09, 2026 · Updated 31 times
Summary
This early-stage trial tested a new drug called GEN3017 in 9 people with CD30-positive Hodgkin or Non-Hodgkin lymphoma that had returned or stopped responding to other treatments. The goal was to check the drug's safety and how well the body tolerates it. The study was terminated early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Helford Clinical Research Hospital
Duarte, California, 91010, United States
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Peter MacCallum Cancer Institute trading as Peter MacCallum Cancer Centre
Melbourne, Victoria, Australia
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.